Similar studies were also conducted by Martinetti et al. [45], who showed that osteoprotegerin (OPG) and osteopontin (OPN) appear to be useful predictors of the outcome of skeletal disease and elevated OPN values may be associated with short survival in advanced breast cancer patients. Here, TNFRSF11B is linked to bone disorder.